#United States #New York #Gross Law Firm #ESSA Pharma #EPIX

ESSA Pharma Inc. Shareholders: Your Rights Matter

In a recent announcement, The Gross Law Firm has issued a crucial alert for shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Those who acquired shares of EPIX during the specified class period, which runs from December 12, 2023, to October 31, 2024, are strongly encouraged to reach out to the law firm before March 25, 2025, to discuss their legal rights and the potential implications of recent allegations against the company.

What’s the Issue?

The allegations leveled against ESSA Pharma revolve around claims that the company issued misleading statements regarding its product's effectiveness. According to the complaint, during the aforementioned class period, the company purportedly failed to disclose critical information indicating that the combination of masofaniten and enzalutamide did not provide any significant efficacy advantage over using enzalutamide alone. This could imply that masofaniten may not be as effective in prostate cancer treatment as previously suggested.

Key Allegations

1. Inefficient Drug Combination: The investigation alleges that the drug combination treatment was less effective than claimed.
2. Misleading Statements: Reports suggest that the company may have overstated masofaniten's clinical, regulatory, and commercial prospects, leading to misinformed decisions by investors.
3. Research Outcomes: It appears that the M-E Combination Study, aimed at evaluating the drug’s efficiency, might not meet its expected outcomes, further skewing investor perceptions of ESSA's viability.

The Importance of Engaging with Legal Support

Shareholders of ESSA Pharma must not procrastinate in protecting their interests. By contacting The Gross Law Firm, shareholders can enroll in a portfolio monitoring service that will provide essential updates and information throughout the case's lifecycle.

Deadlines and Opportunities

It’s vital for investors to register before the March 25, 2025, deadline to either participate or be appointed as lead plaintiffs in any upcoming class action lawsuit. While participation is not contingent on being designated as a lead plaintiff, those who do engage will be better positioned to recover losses should the lawsuit prove successful.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized for its commitment to safeguarding the rights of investors affected by deceptive practices. Their objective is to seek justice and ensure that companies adhere to ethical business practices. In instances where firms’ misrepresentation has inflated stock prices falsely, the law firm aims to hold them accountable and support recovery efforts for aggrieved shareholders.

If you are a shareholder who purchased ESSA Pharma shares during the specified timeframe, do not hesitate to reach out to The Gross Law Firm for support. Remember, acting promptly could protect your investments and contribute to corporate accountability within the pharmaceutical industry.

Contact Information

For further inquiries, shareholders can reach The Gross Law Firm at:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

By taking proactive measures, shareholders can qualify for essential updates and potentially participate in a critical legal action. Stay informed and advocate for your rights as an investor with The Gross Law Firm’s support.